Business Description
Incanthera PLC
ISIN : GB00BGL7YW15
Share Class Description:
AQSE:INC: Ordinary SharesDescription
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | -0.02 | |||||
| Equity-to-Asset | -4.14 | |||||
| Debt-to-Equity | -0.29 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 18.3 | |||||
| 3-Year EPS without NRI Growth Rate | 19.5 | |||||
| 3-Year FCF Growth Rate | 15.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.55 | |||||
| 9-Day RSI | 44.33 | |||||
| 14-Day RSI | 56.19 | |||||
| 6-1 Month Momentum % | 138.1 | |||||
| 12-1 Month Momentum % | 129.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | |||||
| Quick Ratio | 0.16 | |||||
| Cash Ratio | -0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.8 | |||||
| Shareholder Yield % | -0.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -444.01 | |||||
| ROA % | -448.18 | |||||
| ROIC % | -509.67 | |||||
| ROC (Joel Greenblatt) % | -106400 | |||||
| ROCE % | -256.34 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -9.7 | |||||
| EV-to-EBITDA | -9.7 | |||||
| EV-to-FCF | -35.45 | |||||
| Earnings Yield (Greenblatt) % | -10.31 | |||||
| FCF Yield % | -2.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Incanthera PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | |||
| EPS (TTM) (£) | -0.019 | ||
| Beta | 0.13 | ||
| Volatility % | 6.21 | ||
| 14-Day RSI | 56.19 | ||
| 14-Day ATR (£) | 0.007085 | ||
| 20-Day SMA (£) | 0.14225 | ||
| 12-1 Month Momentum % | 129.01 | ||
| 52-Week Range (£) | 0.063 - 0.154 | ||
| Shares Outstanding (Mil) | 77.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Incanthera PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Incanthera PLC Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Incanthera PLC Frequently Asked Questions
What is Incanthera PLC(AQSE:INC)'s stock price today?
The current price of AQSE:INC is £0.13. The 52 week high of AQSE:INC is £0.15 and 52 week low is £0.06.
When is next earnings date of Incanthera PLC(AQSE:INC)?
The next earnings date of Incanthera PLC(AQSE:INC) is .
Does Incanthera PLC(AQSE:INC) pay dividends? If so, how much?
Incanthera PLC(AQSE:INC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers